We are live on ! Find out more
OM

Opaleye Management Portfolio holdings

AUM $1.1B
1-Year Est. Return 197.64%
This Fund
S&P 500
This Quarter Est. Return
+21.76%
1 Year Est. Return
+197.64%
3 Year Est. Return
+748.31%
5 Year Est. Return
+1,163.14%
10 Year Est. Return
+87,953.74%
AUM
$511M
AUM Growth
+$16.2M
Cap. Flow
+$33.5M
Cap. Flow %
6.56%
Top 10 Hldgs %
48.76%
Holding
68
New
20
Increased
11
Reduced
12
Closed
13

Top Buys

Rank Stock Value
1
AFIB
Acutus Medical Inc
AFIB
+$22.8M
2
PCVX icon
Vaxcyte
PCVX
+$12.5M
3
TARA icon
Protara Therapeutics
TARA
+$8.12M
4
CRDF icon
Cardiff Oncology
CRDF
+$7.54M
5
SIOX
Sio Gene Therapies Inc. Common Stock
SIOX
+$6.73M

Top Sells

Rank Stock Value
1
ODT
Odonate Therapeutics, Inc. Common Stock
ODT
+$10.6M
2
QURE icon
uniQure
QURE
+$8.55M
3
APTO
Aptose Biosciences, Inc.
APTO
+$7.38M
4
MTEM
Molecular Templates, Inc.
MTEM
+$6.83M
5
TCDA
Tricida, Inc. Common Stock
TCDA
+$6.55M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ONCT
51
DELISTED
Oncternal Therapeutics, Inc. Common Stock
ONCT
$331K 0.06%
+9,727
New +$477K
PVLA
52
Palvella Therapeutics
PVLA
$2.17B
$300K 0.06%
+1,813
New +$413K
INFI
53
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
$137K 0.03%
+3,171,800
New +$3.26M
BLRX
54
BioLineRX
BLRX
$12.1M
$33K 0.01%
417
– –
MRUS
55
DELISTED
Merus
MRUS
$2K ﹤0.01%
+200
New +$2.58K
ARDX icon
56
Ardelyx
ARDX
$986M
– –
-471,600
Closed -$3.26M
ASRT
57
DELISTED
Assertio
ASRT
– –
-14,667
Closed -$754K
AUTL
58
Autolus Therapeutics
AUTL
$628M
– –
-60,000
Closed -$962K
BTAI icon
59
BioXcel Therapeutics
BTAI
$22.5M
– –
-5,875
Closed -$4.98M
CPRX
60
DELISTED
Catalyst Pharmaceutical
CPRX
– –
-1,155,000
Closed -$5.34M
DNTH icon
61
Dianthus Therapeutics
DNTH
$6.24B
– –
-3,202
Closed -$385K
FENC icon
62
Fennec Pharmaceuticals
FENC
$413M
– –
-171,000
Closed -$1.43M
KALA icon
63
KALA BIO
KALA
$15.7M
– –
-145
Closed -$3.79M
LQDA icon
64
Liquidia Corp
LQDA
$6.26B
– –
-400,000
Closed -$3.37M
QURE icon
65
uniQure
QURE
$3.44B
– –
-270,400
Closed -$8.55M
MTEM
66
DELISTED
Molecular Templates, Inc.
MTEM
– –
-33,000
Closed -$6.83M
TCDA
67
DELISTED
Tricida, Inc. Common Stock
TCDA
– –
-238,300
Closed -$6.55M
ODT
68
DELISTED
Odonate Therapeutics, Inc. Common Stock
ODT
– –
-250,000
Closed -$10.6M
1 2
3

Similar funds

CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
PFM
Premier Fund Managers Guildford, United Kingdom $1.1B AUM 14.42% 1-Year Est. Return
HBCM
Heron Bay Capital Management Bloomfield Hills, Michigan $1.1B AUM 11.31% 1-Year Est. Return
HAS
HBW Advisory Services Simi Valley, California $1.11B AUM 25.66% 1-Year Est. Return
AI
Aperture Investors New York $1.11B AUM 81.44% 1-Year Est. Return
TPA
Trivium Point Advisory Westport, Connecticut $1.1B AUM 28.81% 1-Year Est. Return
ZDA
Zweig-DiMenna Associates New York $1.1B AUM 171.86% 1-Year Est. Return
NW
Naviter Wealth Little Rock, Arkansas $1.1B AUM 33.28% 1-Year Est. Return

Opaleye Management's Q3 2020 Portfolio in Review

As of Q3 2020, Opaleye Management held 68 positions worth $511M, up 3.3% from $495M the previous quarter. Its ten largest holdings account for 49% of the portfolio.

Opaleye Management deployed $33.5M of net new capital in Q3 2020, opening 20 new positions and adding to 11 existing holdings. Its largest new stake was Acutus Medical Inc: 749,990 shares worth $22.4M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Aptose Biosciences, Inc., an estimated $7.38M trimmed.

  • Opaleye Management's largest Q3 2020 buy was Acutus Medical Inc: 749,990 shares worth $22.4M.
  • Opaleye Management added most to Protara Therapeutics in Q3 2020, an estimated $8.12M increase.
  • Opaleye Management's biggest Q3 2020 reduction was Aptose Biosciences, Inc., cutting an estimated $7.38M.
  • Opaleye Management fully exited Odonate Therapeutics, Inc. Common Stock in Q3 2020, selling an estimated $10.6M.
  • Opaleye Management's ten largest holdings make up 49% of its $511M portfolio in Q3 2020.
  • Opaleye Management opened 20 new positions and closed 13 in Q3 2020.
  • Opaleye Management's portfolio value rose 3.3% quarter-over-quarter to $511M.

Based on Opaleye Management's 13F filing for Q3 2020, filed 16 Nov 2020.